How to Get BHRT Online: A 5-Step Guide

What Is BHRT and Why Consider It?

Bioidentical hormone replacement therapy uses hormones that are chemically identical to those the human body produces. Estradiol, progesterone, and testosterone prescribed under BHRT have the same molecular structure as endogenous hormones, unlike conjugated equine estrogens (Premarin) or medroxyprogesterone acetate (Provera), which differ structurally.

The distinction matters clinically. The Endocrine Society's 2015 scientific statement confirmed that FDA-approved bioidentical estradiol and micronized progesterone carry a more favorable cardiovascular and breast safety profile compared with older synthetic combinations. Data from the WHI observational follow-up reinforced that estrogen-alone therapy in women aged 50 to 59 was associated with lower coronary heart disease incidence over 18 years of cumulative follow-up (HR 0.76 to 95% CI 0.58 to 0.99).

Women seeking BHRT online are typically experiencing vasomotor symptoms (hot flashes, night sweats), sleep disruption, vaginal dryness, mood changes, or declining libido during the menopausal transition. The North American Menopause Society (NAMS) 2022 position statement reaffirmed that hormone therapy remains the most effective treatment for these symptoms, particularly when initiated within 10 years of menopause onset.

Telehealth removes several barriers to access. A 2023 cross-sectional analysis published in Menopause found that only 1 in 5 OB-GYN residency programs offer dedicated menopause training, leaving many women without local access to clinicians comfortable prescribing HRT. Online platforms connect patients directly with menopause-trained providers regardless of geography.

Step 1: Screen Your Symptoms and Medical History

The process starts with an intake questionnaire. Every reputable telehealth hormone platform asks you to complete a detailed health screening before booking a consultation. This is not a formality. It determines whether BHRT is safe for you.

Expect questions about your menstrual history, symptom severity, surgical history (especially hysterectomy or oophorectomy), personal and family history of breast cancer, history of blood clots or stroke, liver disease, and current medications. The American College of Obstetricians and Gynecologists (ACOG) identifies absolute contraindications to systemic hormone therapy: active or recent breast cancer, coronary heart disease, active liver disease, unexplained vaginal bleeding, history of venous thromboembolism, and history of stroke.

Your answers shape the clinical path. A woman with an intact uterus needs both estrogen and progesterone (to protect the endometrium), while a woman who has had a hysterectomy may receive estrogen alone. A woman with a history of deep vein thrombosis might be a candidate for transdermal estradiol (which bypasses first-pass hepatic metabolism and does not increase clotting risk) but not oral estrogen [1].

Most platforms use validated symptom scales. The Menopause Rating Scale (MRS) or Greene Climacteric Scale quantifies symptom burden across somatic, psychological, and urogenital domains. Your baseline score becomes the reference point against which treatment response is measured at follow-up visits.

What this step takes: 15 to 30 minutes. No cost at most platforms.

Step 2: Complete Baseline Lab Work

Lab testing is non-negotiable before starting BHRT. A responsible prescriber will not write a hormone prescription based on symptoms alone. Baseline bloodwork confirms hormonal status and rules out conditions that mimic menopause.

The standard panel includes:

• Estradiol (E2): Confirms low estrogen. Postmenopausal levels are typically below 30 pg/mL.
• Follicle-stimulating hormone (FSH): Levels above 30 mIU/mL generally indicate menopause. The Stages of Reproductive Aging Workshop (STRAW+10) criteria use FSH as a key staging biomarker.
• Thyroid-stimulating hormone (TSH): Hypothyroidism can cause fatigue, weight gain, and mood changes that overlap with menopause.
• Complete blood count (CBC) and comprehensive metabolic panel (CMP): Screen for anemia, liver dysfunction, and kidney function.
• Lipid panel: Baseline cardiovascular risk assessment, particularly relevant because oral estrogen affects hepatic lipid metabolism [2].

Some providers also order testosterone (total and free), DHEA-S, and sex hormone-binding globulin (SHBG). These are especially relevant if low libido or fatigue is a primary complaint. The Global Consensus Position Statement on Testosterone Therapy for Women (2019) endorsed testosterone measurement in women with hypoactive sexual desire disorder (HSDD), though it noted that a specific diagnostic threshold has not been established.

You can get labs drawn through the telehealth platform's partner network (Quest, Labcorp, or a mobile phlebotomy service) or bring recent results from your own physician. Labs dated within the prior 90 days are generally accepted.

What this step takes: 1 to 5 days for results, depending on turnaround. Cost ranges from $75 to $250 if out-of-pocket.

Step 3: Consult a Hormone-Trained Clinician

This is the clinical decision point. Your video consultation should last 20 to 45 minutes with a physician, nurse practitioner, or physician assistant who has specific training in menopause medicine or hormone optimization.

During this visit, the clinician reviews your labs, confirms your symptom profile, discusses your goals, and explains the available formulations. A well-structured consultation covers five areas: symptom prioritization, route of delivery, dose selection, risk-benefit discussion, and follow-up timeline.

Route of delivery matters. The KEEPS trial (N=727) compared oral conjugated equine estrogens with transdermal estradiol in recently menopausal women over 4 years and found that transdermal estradiol had a neutral effect on inflammatory markers (C-reactive protein), while oral estrogen raised CRP by approximately 50%. This is one reason why transdermal delivery (patches, gels, sprays) is increasingly preferred, especially in women with obesity, metabolic syndrome, or migraine with aura.

For women with an intact uterus, the REPLENISH trial (N=1,835) demonstrated that the combination of oral estradiol 1 mg plus progesterone 100 mg (Bijuva) significantly reduced hot flashes (74% reduction from baseline at 12 weeks) with endometrial safety over 12 months. Micronized progesterone (Prometrium) remains the guideline-preferred progestogen based on data from the E3N cohort (N=80,377), which associated micronized progesterone with no increased breast cancer risk over 8 years, compared with a significant increase (HR 1.69) for synthetic progestins.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and lead investigator of the WHI hormone trials, has stated: "For most women in their 50s with bothersome menopausal symptoms, the benefits of hormone therapy outweigh the risks when using appropriate formulations and timing" [3].

What this step takes: 20 to 45 minutes. Cost ranges from $99 to $299 for an initial consultation.

Step 4: Receive Your Prescription and Fill It

After your consultation, your prescriber sends the prescription electronically. Where it goes depends on whether you are receiving an FDA-approved product or a compounded formulation.

FDA-approved BHRT options go to any retail or mail-order pharmacy:

• Transdermal estradiol patches: Vivelle-Dot (0.025 to 0.1 mg/day), Climara (0.025 to 0.1 mg/day)
• Topical estradiol gel: EstroGel (0.06%), Divigel (0.25 to 1.0 mg)
• Oral micronized progesterone: Prometrium (100 mg or 200 mg)
• Combined estradiol/progesterone: Bijuva (estradiol 1 mg / progesterone 100 mg)
• Vaginal estradiol: Vagifem (10 mcg tablet), Imvexxy (4 mcg or 10 mcg)

Compounded BHRT goes to a 503A (patient-specific) or 503B (outsourcing facility) compounding pharmacy. Compounded options include bi-est or tri-est creams, progesterone troches, testosterone cream (typically 0.5 to 2 mg/day for women), and subcutaneous pellets.

The FDA's position is clear: FDA-approved bioidentical hormones are preferred over compounded versions because they undergo rigorous testing for potency, purity, and consistency. Compounded products are not FDA-approved and are not subject to the same manufacturing standards. The National Academies of Sciences, Engineering, and Medicine (NASEM) 2020 report recommended that compounded BHRT should only be used when an FDA-approved product cannot meet a patient's clinical need (e.g., allergy to an inactive ingredient, need for a dose not commercially available).

Cost varies significantly. Generic transdermal estradiol patches run $20 to $45/month with insurance or GoodRx coupons. Prometrium generic runs $15 to $30/month. Compounded formulations typically cost $50 to $200/month and are rarely covered by insurance.

What this step takes: 1 to 3 days for retail pharmacy; 5 to 10 days for compounded prescriptions shipped to your door.

Step 5: Follow Up and Optimize Your Dose

Starting BHRT is not a one-time event. Dose optimization requires iterative follow-up. NAMS and the Endocrine Society both recommend the first follow-up visit at 6 to 12 weeks after initiation, with subsequent visits every 6 to 12 months [4].

At your first follow-up, the clinician assesses symptom response (using the same validated scale from Step 1), checks for side effects (breast tenderness, bloating, breakthrough bleeding), and reviews repeat labs. Estradiol levels on transdermal therapy should generally fall in the 40 to 100 pg/mL range. Progesterone is typically not monitored by blood level unless cycle timing or endometrial protection is in question.

Dose adjustments are common. The Cochrane review of HRT for menopausal vasomotor symptoms (2017) found a dose-response relationship: higher estradiol doses produced greater symptom reduction but also more side effects (OR 1.41 for breast tenderness with higher doses). The clinical goal is the lowest effective dose that adequately controls symptoms.

If you have been prescribed testosterone for HSDD, the International Society for the Study of Women's Sexual Health (ISSWSH) recommends checking free testosterone at 3 to 6 weeks to ensure levels remain in the premenopausal physiologic range. Supraphysiologic levels increase the risk of acne, hirsutism, and adverse lipid changes.

Long-term monitoring includes annual mammography (per USPSTF guidelines), periodic endometrial assessment if unscheduled bleeding occurs, and bone density screening (DXA) at age 65 or earlier if risk factors are present.

What this step takes: 15 to 30 minutes per follow-up visit. Cost ranges from $49 to $149 per telehealth follow-up.

Choosing the Right Telehealth Platform

Not all online hormone therapy providers are equal. When evaluating platforms, look for these markers of clinical quality.

Prescriber credentials matter. Your provider should be a licensed MD, DO, NP, or PA in your state. Ask whether they have completed menopause-specific training through NAMS, the American Academy of Anti-Aging Medicine (A4M), or equivalent programs. Board certification in endocrinology, reproductive endocrinology, or OB-GYN is a strong indicator.

Lab requirements signal rigor. Any platform that prescribes hormones without lab work is a red flag. The Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Women (2019) explicitly recommends against prescribing hormones based on symptoms alone, because symptom overlap with thyroid disease, depression, and sleep disorders is extensive.

Pharmacy partnerships indicate quality control. Ask whether compounded prescriptions go to PCAB-accredited (Pharmacy Compounding Accreditation Board) pharmacies. PCAB accreditation requires third-party potency and sterility testing. A 2019 FDA survey of compounded hormone products found that 34% of tested samples failed potency specifications, underscoring the importance of pharmacy quality.

Follow-up cadence reflects commitment to outcomes. Platforms that schedule proactive follow-ups (not just "call us if you have problems") produce better outcomes. A 2021 study in Telemedicine and e-Health found that structured telehealth follow-up for hormone therapy was associated with 89% patient satisfaction and equivalent symptom control compared with in-person care.

Safety Considerations and Contraindications

BHRT is safe for most symptomatic menopausal women, but it is not appropriate for everyone. The safety profile depends on formulation, dose, route, and individual risk factors.

The WHI trials established that the risk-benefit ratio of hormone therapy is most favorable when started within 10 years of menopause or before age 60. This "timing hypothesis" has been consistently supported by subsequent analyses. Women who start HRT at age 50 have a very different risk profile than those starting at age 70 [5].

Transdermal estradiol does not increase venous thromboembolism (VTE) risk. The ESTHER case-control study (N=881) found no increase in VTE with transdermal estrogen (OR 0.9 to 95% CI 0.5 to 1.6), while oral estrogen carried a significantly elevated risk (OR 4.2). This distinction guides prescribing for women with obesity (BMI ≥30), who already carry higher baseline VTE risk.

Breast cancer risk depends on the progestogen. The E3N French cohort data showed that estradiol combined with micronized progesterone carried no excess breast cancer risk over 8 years, while estradiol combined with synthetic progestins increased risk by 69% [6]. This evidence base drives the preference for micronized progesterone in BHRT protocols.

Women with a BRCA1 or BRCA2 mutation who have undergone risk-reducing bilateral salpingo-oophorectomy before natural menopause may be candidates for HRT until the average age of menopause (51 years), per ACOG Committee Opinion 601. The premature surgical menopause itself carries cardiovascular and bone risks that may outweigh the theoretical breast cancer concern, especially for BRCA2 carriers.

What BHRT Costs Without Insurance

Transparency on cost prevents surprises. Here is a realistic breakdown for the first year:

• Initial consultation: $99 to $299
• Baseline labs: $75 to $250 (often included in platform fee)
• FDA-approved medications: $240 to $540/year (generic patches + generic Prometrium)
• Compounded medications: $600 to $2,400/year
• Follow-up visits (2 to 3 per year): $98 to $447/year
• Repeat labs (1 to 2 per year): $75 to $250/year

Total first-year range: approximately $587 to $3,646, depending on whether you use FDA-approved generics or compounded formulations.

Many FSA and HSA accounts cover telehealth hormone therapy consultations and prescription costs. Some platforms accept insurance for the consultation portion while prescriptions are filled separately through your pharmacy benefit.

The cost of not treating symptomatic menopause is worth quantifying. A 2015 analysis in Menopause estimated that menopausal women with untreated vasomotor symptoms incurred $1,346 to $2,234 more in annual direct healthcare costs compared with asymptomatic women, driven by increased office visits, sleep medication use, and mood disorder treatment.

Timeline: From Signup to Symptom Relief

Knowing what to expect reduces anxiety. Here is a typical timeline:

• Day 1: Complete intake questionnaire (15 to 30 minutes)
• Days 2 to 5: Lab draw and results
• Days 5 to 10: Video consultation with prescriber
• Days 7 to 14: Prescription filled and delivered
• Weeks 2 to 4: Initial symptom improvement (hot flash frequency and severity)
• Weeks 4 to 8: Sleep quality, mood, and energy improvements
• Weeks 6 to 12: First follow-up visit and dose adjustment if needed
• Month 3 to 6: Full therapeutic benefit for most women

The REPLENISH trial showed statistically significant hot flash reduction as early as week 4, with progressive improvement through week 12. Vaginal dryness and urogenital symptoms may take 8 to 12 weeks of local estrogen therapy to reach maximal improvement.